Effect of serum derived blocking factor (SDBF) on platelet associated-IgG.
We analyzed the effect of an unknown factor, which derived from serum, on platelet associated IgG (PA-IgG) and we established the novel immunofluorescence method to measure the level of PA-IgG. Blood samples were obtained from 20 patients with idiopathic thrombocytopenic purpura (ITP). After the treatment of platelets with neuraminidase, the value of PA-IgG positive platelets (%PA-IgG) were significantly increased in patients with ITP, but not in controls. When the platelets pretreated with neuraminidase were incubated with human serum, %PA-IgG was remarkably decreased in ITP patients. In healthy individuals, when platelets bound to aggregated human IgG pretreated with human serum, the binding of FITC-conjugated anti-human IgG was inhibited. And the value of mouse anti-GP II b/III a monoclonal antibody positive platelets was decreased, when the platelets preincubated with mouse serum. The binding of FITC-conjugated anti-human IgG and anti-mouse IgG antibody was apparently inhibited by some unknown factor in serum. Our results showed that this substance had species specificity. We called this substance "Serum Derived Blocking Factor (SDBF)".